Contact this trialFirst, we need to learn more about you.
Endothelin Receptor Antagonist
Ambrisentan + Sotagliflozin for Type 1 Diabetes Kidney Protection
Recruiting1 awardPhase 2
Aurora, Colorado
This trial tests if a combination of two medicines can help protect kidneys, reduce fluid retention and stop ketogenesis in people with Type 1 Diabetes.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.